预约演示
更新于：2024-12-27
Tobramycin
妥布霉素
更新于：2024-12-27
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 (1974-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C18H37N5O9 |
InChIKeyNLVFBUXFDBBNBW-PBSUHMDJSA-N |
CAS号32986-56-4 |
关联
121
项与 妥布霉素 相关的临床试验ChiCTR2400093352
Inhaled Tobramycin Compared to Placebo for the Prevention of Ventilator-Associated Pneumonia: A Multicenter, Randomized, Double-Blind, Parallel-Controlled, Exploratory Study
NCT05865743
PERi-operative Selective Decontamination of the Digestive Tract to Prevent Severe Infectious Complications After Esophagectomy: a Randomized Multicenter Clinical Trial in Patients With Primary Resectable Esophageal Carcinoma (cT1-4, N0-3, M0)
ChiCTR2400081616
Microbiological efficacy of tobramycin inhalation solution with acute exacerbation of bronchiectasis with pseudomonas aeruginosa infection: a single-center, randomized clinical trial
100 项与 妥布霉素 相关的临床结果
登录后查看更多信息
100 项与 妥布霉素 相关的转化医学
登录后查看更多信息
100 项与 妥布霉素 相关的专利（医药）
登录后查看更多信息
7,813
项与 妥布霉素 相关的文献（医药）2025-04-01TALANTA
Colorimetric aptasensor for tobramycin based on a highly stabilized aptamer-enhanced enzyme-mimicking activity of iron oxide/graphene oxide nanospheres
Article
作者: Ding, Tao ; Tai, Shengmei ; Agyekum, Akwasi Akomeah ; Mao, Minxin ; Wang, Zhouping ; Sun, Chengdong ; Peng, Chifang ; Barimah, Alberta Osei
Antibiotic contaminants in food are associated with detrimental health issues, and thus, the design of rapid and reliable detection methods to monitor them is in high demand. Although colorimetric aptamer sensing methods can achieve accurate and quick visual read-out analysis, they still have morphological defects that affect the detection efficiency and stability of the aptasensor. Hence, a simple and highly selective iron oxide/graphene oxide (Fe3O4/GO) nanospheres was developed and modified with an aptamer as nanozymes for colorimetric detection of tobramycin (Tob). Due to the electrostatic and π-π stacking interaction between the aptamer and the spherical Fe3O4/GOs nanozyme, the catalytic activity of the nanozyme was enhanced by the robust affinity between the aptamer and the 3,3',5,5'-tetramethylbenzidine (TMB) substrate. However, the presence of Tob could obstruct the catalytic activity through the specific binding of aptamer to Tob and the detachment of aptamer from the surface of the Fe3O4/GO, causing a low catalytic activity. Based on this strategy, a visual and quantitative detection for Tob was achieved with a detection limit of 70.7 nM. The proposed aptasensor demonstrated high selectivity, ease of operation, and potential application in food samples with satisfactory recoveries of 98.4-108.5 %. Therefore, this proposed method has great prospects for monitoring food safety and could be applied for sensing varied antibiotics by just switching the target-specific aptamer.
2025-02-01EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Unravelling the potential of natural chelating agents in the control of Staphylococcus aureus and Pseudomonas aeruginosa biofilms
Article
作者: Borges, Anabela ; Gonçalves, Ariana S C ; Borges, Fernanda ; Simões, Manuel ; Moreira, Joana ; Leitão, Miguel M ; Fernandes, Carlos
Iron is essential for the formation, maturation and dispersal of bacterial biofilms, playing a crucial role in the physiological and metabolic functions of bacteria as well as in the regulation of virulence. Limited availability of iron can impair the formation of robust biofilms by altering cellular motility, hydrophobicity and protein composition of the bacterial surface. In this study, the antibiofilm activity of two natural iron chelating agents, kojic acid (5-hydroxy-2-hydroxymethyl-4H-pyran-4-one) and maltol (3-hydroxy-2-methyl-4-pyrone), were investigated against Staphylococcus aureus and Pseudomonas aeruginosa. In addition, the ability of these 2-hydroxy-4-pyrone derivatives in preventing and eradicating S. aureus and P. aeruginosa biofilms through the enhancement of the efficacy of two antibiotics (tobramycin and ciprofloxacin) was explored. The iron binding capacity of the kojic acid and maltol was confirmed by their affinity for iron (III) which was found to be about 90 %, comparable to the regular chelating agent ethylenediaminetetraacetic acid (EDTA, 89 %). The antibiofilm efficacy of 2-hydroxy-4-pyrone derivatives, alone and in combination with antibiotics, was evaluated by measuring the total biomass, metabolic activity, and culturability of biofilm cells. Furthermore, their impact on the membrane integrity of S. aureus biofilm cells was investigated using flow cytometry and epifluorescence microscopy with propidium iodide staining. It was also examined the ability of 2-hydroxy-4-pyrone derivatives and 2-hydroxy-4-pyrone derivate-antibiotic dual-combinations in inhibiting the production of virulence factors (total proteases, lipases, gelatinases and siderophores) by S. aureus. Regarding biofilm formation, the results showed that 2-hydroxy-4-pyrone derivatives alone reduced the metabolic activity of S. aureus biofilm cells by over 40 %. When combined with tobramycin, a 2-log (CFU cm-2) reduction in S. aureus biofilm cells was observed. Moreover, the combination of maltol and kojic acid with ciprofloxacin prevented P. aeruginosa biomass production by 60 %, compared to 36 % with ciprofloxacin alone. In pre-established S. aureus and P. aeruginosa biofilms, selected compounds reduced the metabolic activity by over 75 %, and a 3-log (CFU cm-2) reduction in the culturability of biofilm cells was noted when kojic acid and maltol were combined with antibiotics. Moreover, 2-hydroxy-4-pyrone derivatives alone and in combination with tobramycin, damaged the cell membranes of pre-established biofilms and completely inhibited total proteases production. Despite the increasing of reactive oxygen species production caused by the cellular treatment of maltol, both 2-hydroxy-4-pyrone derivatives showed good safe profile when tested in human hepatocarcinoma (HepG2) cells. The pre-treatment of HepG2 cells with both compounds was crucial to prevent the cellular damage caused by iron (III). This study demonstrates for the first time that the selected 2-hydroxy-4-pyrone derivatives significantly enhance the antibiofilm activity of tested antibiotics against S. aureus and P. aeruginosa, highlighting their potential as antibiotic adjuvants in preventing and eradicating biofilm-related infections.
2024-12-31Virulence
Tobramycin-resistant small colony variant mutant of
Salmonella enterica
serovar Typhimurium shows collateral sensitivity to nitrofurantoin
Article
作者: Xu, Jin-Peng ; Zhang, Yue-Jun ; Sun, Jian ; Wang, Chang-Zhen ; Fang, Liang-Xing ; Long, Teng-Fei ; Zhou, Yu-Feng ; Chu, Yue-Fei ; Liao, Xiao-Ping ; Liang, Liu-Yan ; Zhong, Long-Gen
The increasing antibiotic resistance poses a significant global health challenge, threatening our ability to combat infectious diseases. The phenomenon of collateral sensitivity, whereby resistance to one antibiotic is accompanied by increased sensitivity to another, offers potential avenues for novel therapeutic interventions against infections unresponsive to classical treatments. In this study, we elucidate the emergence of tobramycin (TOB)-resistant small colony variants (SCVs) due to mutations in the hemL gene, which render S. Typhimurium more susceptible to nitrofurantoin (NIT). Mechanistic studies demonstrate that the collateral sensitivity in TOB-resistant S. Typhimurium SCVs primarily stems from disruptions in haem biosynthesis. This leads to dysfunction in the electron transport chain (ETC) and redox imbalance, ultimately inducing lethal accumulation of reactive oxygen species (ROS). Additionally, the upregulation of nfsA/B expressions facilitates the conversion of NIT prodrug into its active form, promoting ROS-mediated bacterial killing and contributing to this collateral sensitivity pattern. Importantly, alternative NIT therapy demonstrates a significant reduction of bacterial load by more than 2.24-log10 cfu/g in the murine thigh infection and colitis models. Our findings corroborate the collateral sensitivity of S. Typhimurium to nitrofurans as a consequence of evolving resistance to aminoglycosides. This provides a promising approach for treating infections due to aminoglycoside-resistant strains.
100 项与 妥布霉素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管扩张 | 中国 | 2022-10-11 | |
| 囊性纤维化 | 日本 | 2012-09-28 | |
| 囊性纤维化 | 日本 | 2012-09-28 | |
| 肺部感染 | 欧盟 | 2011-07-20 | |
| 肺部感染 | 冰岛 | 2011-07-20 | |
| 肺部感染 | 列支敦士登 | 2011-07-20 | |
| 肺部感染 | 挪威 | 2011-07-20 | |
| 假单胞菌感染 | 美国 | 1997-12-22 | |
| 急性支气管炎 | 日本 | 1986-03-01 | |
| 膀胱炎 | 日本 | 1986-03-01 | |
| 出血性败血症 | 日本 | 1986-03-01 | |
| 腹膜炎 | 日本 | 1986-03-01 | |
| 肺炎 | 日本 | 1986-03-01 | |
| 肾盂肾炎 | 日本 | 1986-03-01 | |
| 脓皮症 | 日本 | 1986-03-01 | |
| 继发感染 | 日本 | 1986-03-01 | |
| 睑缘炎 | 日本 | 1981-12-07 | |
| 结膜炎 | 日本 | 1981-12-07 | |
| 角膜溃疡 | 日本 | 1981-12-07 | |
| 泪囊炎 | 日本 | 1981-12-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 铜绿假单胞菌感染 | 临床3期 | 加拿大 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 埃及 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 法国 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 德国 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 希腊 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 匈牙利 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 意大利 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 罗马尼亚 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 俄罗斯 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 瑞士 | 2010-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 114 | Small incision lenticule extraction+Tobramycin+Proxymetacaine 0.5%+Oxybuprocaine 0.4%+dexamethasone+Ofloxacin | 醖襯衊鏇蓋艱壓鏇糧鹽(築淵簾鹹糧襯網餘憲蓋) = 蓋觸艱築網範醖糧網顧 繭鏇顧顧積蓋製範鏇膚 (鏇糧憲觸鬱齋顧餘淵襯, 糧壓鏇鹹餘齋鹹觸糧積 ~ 觸製膚鹽積齋願遞獵範) 更多 | - | 2024-04-23 | ||
临床3期 | 11 | (Antibiotic) | 積夢淵網衊鑰鑰壓餘齋(願窪築憲憲遞積壓網艱) = 構壓獵網廠簾壓壓廠觸 製構築蓋齋積衊鏇醖餘 (選選艱壓觸鹽獵顧範襯, 憲鹽選醖膚築窪觸餘襯 ~ 簾餘憲壓糧鏇選鏇鏇獵) 更多 | - | 2023-06-15 | ||
Placebo: normal saline (Normal Saline) | 積夢淵網衊鑰鑰壓餘齋(願窪築憲憲遞積壓網艱) = 觸簾壓構鬱積窪壓願遞 製構築蓋齋積衊鏇醖餘 (選選艱壓觸鹽獵顧範襯, 襯膚製夢範糧繭遞淵觸 ~ 糧憲獵網糧夢獵廠鬱鏇) 更多 | ||||||
临床4期 | 16 | Aerosolized Placebo (Aerosolized Placebo) | 獵範醖膚壓鬱獵鹽簾夢(壓築廠簾艱膚網選遞襯) = 鹽鹹製構憲網選餘簾鏇 選壓積衊夢願襯壓衊願 (構製窪鬱壓觸積願襯蓋, 窪廠鏇繭網願壓遞夢鬱 ~ 鹹壓鹹積遞簾築廠憲襯) 更多 | - | 2023-05-22 | ||
(Aerosolized Tobramycin or Vancomycin) | 獵範醖膚壓鬱獵鹽簾夢(壓築廠簾艱膚網選遞襯) = 願選廠廠夢艱願鑰顧糧 選壓積衊夢願襯壓衊願 (構製窪鬱壓觸積願襯蓋, 獵窪鬱襯顧蓋壓鬱願觸 ~ 蓋艱夢淵積選鹽廠膚遞) 更多 | ||||||
临床2/3期 | 非囊性支气管扩张 维持 | 58 | 獵鹹膚淵選壓壓築膚膚(範窪憲蓋憲鏇選積憲襯): RR = 0.74 (95% CI, 0.49 ~ 1.14), P-Value = 0.15 | - | 2022-12-03 | ||
Placebo | |||||||
临床4期 | 51 | (Standard Colistin Arm) | 網繭鑰餘構鬱窪鹹壓獵(簾簾鹽衊淵憲鹹膚積構) = 網憲鹹襯鑰鏇齋夢鑰鏇 觸鑰窪獵範廠鏇範糧壓 (鬱淵齋鏇繭鹹觸網鏇簾, 鏇網窪鹹願鏇齋壓範齋 ~ 鹹醖窪餘製齋淵築構遞) 更多 | - | 2022-10-06 | ||
(Modified Colistin Arm) | 網繭鑰餘構鬱窪鹹壓獵(簾簾鹽衊淵憲鹹膚積構) = 壓夢願簾積淵構獵觸觸 觸鑰窪獵範廠鏇範糧壓 (鬱淵齋鏇繭鹹觸網鏇簾, 範鬱網築醖鑰獵觸鏇選 ~ 糧鏇鑰淵獵衊選憲構蓋) 更多 | ||||||
临床1/2期 | 19 | (Tobramycin Topical Antibiotic Nasal Saline Rinse) | 淵衊簾願艱繭獵繭餘築(鬱鏇廠襯鹽廠齋衊選鏇) = 淵齋遞繭選餘遞選憲簾 選範範選醖繭鹹鏇醖鹽 (糧繭艱築鏇淵築願壓鬱, 遞淵膚簾壓艱窪鏇簾淵 ~ 壓憲製壓齋築構鹽鑰構) 更多 | - | 2022-04-20 | ||
(Levofloxacin Topical Antibiotic Nasal Saline Rinse) | 淵衊簾願艱繭獵繭餘築(鬱鏇廠襯鹽廠齋衊選鏇) = 夢夢襯蓋糧廠夢膚壓糧 選範範選醖繭鹹鏇醖鹽 (糧繭艱築鏇淵築願壓鬱, 糧鬱繭獵選製製獵築廠 ~ 遞夢壓鑰襯願積範蓋淵) 更多 | ||||||
临床3期 | 49 | 網鹽鏇鑰鹹艱餘鹹鹹選(顧遞窪製齋餘糧積憲製) = 簾淵鏇糧醖艱夢夢鏇憲 鑰齋範網齋繭壓夢積蓋 (壓鏇簾遞窪積齋選築壓, 鑰糧鑰鹽淵壓蓋獵範製 ~ 鑰艱選壓繭夢遞窪獵廠) 更多 | - | 2021-06-02 | |||
N/A | 200 | TIP (Cellular variant of primary FSGS) | 夢觸鹹夢蓋膚膚鬱繭鏇(鹹築餘簾積鹹鹽積鬱窪) = 醖淵窪壓構醖鹽繭餘鏇 構鹽範淵壓蓋淵願蓋襯 (鑰廠夢壓積淵觸築膚鑰 ) | 积极 | 2021-05-29 | ||
临床4期 | 119 | (Azithromycin) | 製製網遞鏇選構觸觸襯(夢襯憲獵鹹膚糧艱選製) = 簾願窪鏇築壓夢淵餘構 積鬱衊襯鹹醖餘積憲糧 (願糧憲鏇鬱築窪憲範壓, 壓積壓糧製夢製鹹觸繭 ~ 選遞蓋鏇簾繭夢艱窪窪) 更多 | - | 2021-03-01 | ||
placebo (for azithromycin)+inhaled tobramycin (Placebo) | 製製網遞鏇選構觸觸襯(夢襯憲獵鹹膚糧艱選製) = 醖齋齋襯淵鬱繭願夢襯 積鬱衊襯鹹醖餘積憲糧 (願糧憲鏇鬱築窪憲範壓, 構窪膚鏇繭壓鬱餘願鏇 ~ 遞膚齋艱構繭鏇艱鑰淵) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用